Ondrej Fiala1, Milos Pesek2, Jindrich Finek3, Ondrej Topolcan4, Jaroslav Racek5, Martin Svaton2, Radek Kucera4, Marek Minarik6, Lucie Benesova7, Zbynek Bortlicek8, Renata Chloupkova8, Alexandr Poprach9, Tomas Buchler10. 1. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic fiala.o@centrum.cz. 2. Department of Pneumology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic. 3. Department of Oncology and Radiotherapy, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic. 4. Department of Nuclear Medicine, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic. 5. Istitute of Clinical Biochemistry and Hematology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Prague, Czech Republic. 6. Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic Department of Analytical Chemistry, Faculty of Sciences, Charles University in Prague, Prague, Czech Republic. 7. Center for Applied Genomics of Solid Tumours, Genomac Research Institute, Prague, Czech Republic. 8. Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 9. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic. 10. Department of Oncology and First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
Abstract
BACKGROUND: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. PATIENTS AND METHODS: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. RESULTS: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). CONCLUSION: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC. Copyright
BACKGROUND: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. PATIENTS AND METHODS: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. RESULTS: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). CONCLUSION: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC. Copyright
Authors: Zhibo Zhang; Ye Li; Xiang Yan; Qi Song; Guoqiang Wang; Yi Hu; Shunchang Jiao; Jinliang Wang Journal: Cancer Med Date: 2019-03-07 Impact factor: 4.452
Authors: Lei Liu; Ying He; Ge Ge; Lei Li; Ping Zhou; Yihan Zhu; Huairong Tang; Yan Huang; Weimin Li; Li Zhang Journal: PLoS One Date: 2017-08-02 Impact factor: 3.240